HEIDELBERG UNIVERSITY

Nanoparticle Vaccines Show Promise Against HPV-Related Cancers in Preclinical Studies

- Two independent research teams have developed nanoparticle-based therapeutic vaccines that successfully suppressed HPV-related tumors in preclinical mouse models, addressing a critical gap in treatment for existing HPV-associated cancers. - The UT Southwestern nanovaccine achieved remarkable efficacy in metastatic disease, with 71% survival at 60 days compared to zero survival with current standard checkpoint inhibitors alone, and 100% survival when combined with checkpoint therapy. - Both vaccine platforms utilize different nanoparticle carriers to deliver HPV antigens and immune stimulants, demonstrating the versatility of nanotechnology approaches for cancer immunotherapy. - The therapeutic vaccines target patients with established HPV-related cancers such as cervical and head-and-neck cancers, where preventive HPV vaccines offer no benefit and treatment options remain limited.